Interestingly, a recent Phase 2 Clinical Trial is currently determining the therapeutic effects of Tazemetostat in patients with solid tumors and non-Hodgkin lymphoma that do not respond to standard treatments and have EZH2, SMARCB1, or SMARCA4 gene mutations (NCT03213665)67. Here, SMARCA4 is linked to non-Hodgkin lymphoma.